Patents by Inventor Kamalkishore Pati
Kamalkishore Pati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11857520Abstract: A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.Type: GrantFiled: December 4, 2019Date of Patent: January 2, 2024Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20230364068Abstract: A method of providing an IV nimodipine infusion regimen using a solubilized nimodipine solution suitable for IV administration is disclosed. The IV nimodipine infusion regimen provides a constant infusion rate over the (entire) 24 hour period supplemented with higher infusions of nimodipine at set intervals to duplicate the 24 hour AUC and Cmax of an oral nimodipine dose.Type: ApplicationFiled: May 10, 2023Publication date: November 16, 2023Applicant: ACASTI PHARMA U.S., INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Kamalkishore Pati, Vimal Kavuru
-
Publication number: 20220062256Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: November 10, 2021Publication date: March 3, 2022Applicant: GRACE THERAPEUTICS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200397769Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: September 8, 2020Publication date: December 24, 2020Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Patent number: 10799486Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: July 26, 2018Date of Patent: October 13, 2020Assignee: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200197338Abstract: A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.Type: ApplicationFiled: December 4, 2019Publication date: June 25, 2020Applicant: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200163947Abstract: A method of treating a human patient suffering from subarachnoid hemorrhage (SAH), intra-cerebral hemorrhage, and traumatic brain injuries (TBI), and the like, comprising administering a nimodipine formulation suitable for parenteral injection, e.g., either via the subcutaneous or intramuscular route, is disclosed.Type: ApplicationFiled: October 31, 2019Publication date: May 28, 2020Applicant: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20190255033Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: February 21, 2019Publication date: August 22, 2019Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20180325882Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: July 26, 2018Publication date: November 15, 2018Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Patent number: 10092553Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: June 30, 2017Date of Patent: October 9, 2018Assignee: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20170296522Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: June 30, 2017Publication date: October 19, 2017Applicant: GRACE THERAPEUTICS LLCInventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Patent number: 9676679Abstract: The present disclosure is directed to a traceless directing group in a radical cascade. The chemo- and regioselectivity of the initial attack in skipped oligoalkynes is controlled by a propargyl alkoxy moiety. Radical translocations lead to the boomerang return of radical center to the site of initial attack where it assists to the elimination of the directing functionality via ?-scission in the last step of the cascade. In some aspects, the reaction of the present invention is catalyzed by a stannane moiety, which allows further via facile reactions with electrophiles as well as Stille and Suzuki cross-coupling reactions. This selective radical transformation opens a new approach for the controlled transformation of skipped oligoalkynes into polycyclic ribbons of tunable dimensions.Type: GrantFiled: November 3, 2015Date of Patent: June 13, 2017Assignee: The Florida State University Research Foundation, Inc.Inventors: Igor V. Alabugin, Kamalkishore Pati
-
Publication number: 20160145276Abstract: The present disclosure is directed to a traceless directing group in a radical cascade. The chemo- and regioselectivity of the initial attack in skipped oligoalkynes is controlled by a propargyl alkoxy moiety. Radical translocations lead to the boomerang return of radical center to the site of initial attack where it assists to the elimination of the directing functionality via ?-scission in the last step of the cascade. In some aspects, the reaction of the present invention is catalyzed by a stannane moiety, which allows further via facile reactions with electrophiles as well as Stille and Suzuki cross-coupling reactions. This selective radical transformation opens a new approach for the controlled transformation of skipped oligoalkynes into polycyclic ribbons of tunable dimensions.Type: ApplicationFiled: November 3, 2015Publication date: May 26, 2016Inventors: Igor V. Alabugin, Kamalkishore Pati